Physician profile
Efe Efemini
NPI 1205919990
$1,609.66
in general payments reported to CMS, 2019-2025
13 companies · $97.79 in 2025
The $97.79 reported for 2025 was more than what a typical Hospitalist provider received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $279 · 2021: $459 · 2022: $197 · 2023: $279 · 2025: $97.79.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $377.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $377.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $699.09 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $207.13 | 2021-2023 | Lokelma |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.86 | 2020-2023 | Combivent Respimat, Spiriva Respimat, Stiolto Respimat |
| Alexion Pharmaceuticals, INC. | $122.81 | 2023 | Soliris |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $113.66 | 2021-2025 | Lifevest |
| Medtronic USA, INC. | $72.64 | 2020 | |
| Pfizer INC. | $48.35 | 2023 | |
| E.R. Squibb & Sons, L.L.C. | $44.13 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.75 | 2020-2021 | |
| Gilead Sciences, INC. | $18.87 | 2023 | |
| Boston Scientific Corporation | $18.48 | 2020 | |
| Novartis Pharmaceuticals Corporation | $16.75 | 2019 | |
| Abbott Laboratories | $16.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Efe Efemini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.